Unlock instant, AI-driven research and patent intelligence for your innovation.

Materials and methods for immunizing against fiv infection.

An immunogen, HIV-1 technology, applied in chemical instruments and methods, biochemical equipment and methods, pharmaceutical formulations, etc., can solve problems such as little understanding of the relationship

Inactive Publication Date: 2008-05-14
UNIV OF FLORIDA RES FOUNDATION INC
View PDF28 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although HIV and FIV subtype classification is based on genotype (Sodora et al., 1994; Rigby et al., 1993 and Louwagie et al., 1993), much is known about the interrelationship between genotype and immune type of subtype few

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Materials and methods for immunizing against fiv infection.
  • Materials and methods for immunizing against fiv infection.
  • Materials and methods for immunizing against fiv infection.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0097]Each of the four SPF cats (n=4) was immunized with HIV-1 vaccine formulation A or HIV-1 vaccine formulation B four times at 3 week intervals and three weeks after the last boost with 15 times the cat infection dose (CID 50 ) FIV from in vivo sources Bangston Inoculum attack. The other four SPF cats (control group) did not receive immunization but were similarly challenged with FIV. HIV-1 vaccine preparation A consists of 200μg HIV-1 mixed in 0.5ml Ribi adjuvant system UCD1 p24, 25μg HIV-1 IIIB gp120 (ImmunoDiagnostics Inc., Woburn, MA) and 25μg HIV-1 IIIB gp160 (ImmunoDiagnostics Inc.), wherein the Ribi adjuvant system contains a cell wall skeleton (CWS) component containing 5 μg recombinant human interleukin-12 (rHuIL-12) (25 μg cell wall skeleton per dose) (Corixa Corp. , Seattle, WA). HIV-1 vaccine formulation B consists of 200μg HIV-1 mixed with 0.5ml Ribi adjuvant system CWS component containing 5μgrHuIL-12 UCD1 p24 composition. Recombinant HIV-1 UCD1 p24 was produced i...

Embodiment 2

[0101] In subsequent studies, each of the four SPF cats was treated with HIV-1 / UCD1 (HIV-1 UCD1 )p24 or HIV-1 / LAV (HIV-1 LAV ) The p24 vaccine is immunized at 250 μg per dose, wherein the vaccine is dissolved in 1 ml Ribi adjuvant (25 μg CWS (cell wall skeleton) per dose) supplemented with 5 μg recombinant human IL-12 (rHuIL-12) per dose. Another group of three SPF cats received HIV-1 without Ribi adjuvant or rHuIL-12 UCD1 p24 to evaluate the importance of adjuvants. Cats in the control group received Ribi adjuvant or PBS. All cats were vaccinated three (3) times at three (3) week intervals and received 15 CID three weeks after the last immunization 50 FIV-Bangston (FIV Bang )attack. As shown in Table 2, four animals used HIV-1 with adjuvant UCD1 Four of the p24 immunized cats (4 / 4) were not FIV infected at the dose of FIV infection after challenge with all four control cats. Use adjuvanted HIV-1 UCD1 Protected cats vaccinated with p24 are negative for FIV infection at 54 weeks af...

Embodiment 3

[0103] Conduct another study to determine HIV-1 LAV Is the protection induced by p24 vaccine reproducible? In this study, three SPF cats used 200μg of HIV-1 per dose LAV The p24 vaccine is immunized, wherein the vaccine is formulated in 1 ml Ribi adjuvant (25 μg CWS (cell wall skeleton) per dose) supplemented with 5 μg rHuIL-12 per dose. In addition, each of the three SPF cats used 200μg of FIV per dose Bang p24 or FIV-Petaluma+Shizuoka (FIV Pet / Shi ) p24 vaccine immunization, wherein the vaccine is formulated in 1 ml Ribi adjuvant (25 μg CWS (cell wall skeleton) per dose) supplemented with 5 μg rHuIL-12 per dose. FIV Pet / Shi The p24 vaccine consists of 130 μg FIV dissolved in Ribi adjuvant supplemented with rHuIL-12 Pet p24 and 70μg FIV shi p24 composition. Three control cats received adjuvant. The immunization and challenge protocol (including challenge inoculum and dose) is the same as described in Example 2. As shown in Table 3, use HIV-1 LAV Three of the three cats vaccinated...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods and compositions for preventing FIV infection in felines using immunogens derived from primate immunodeficiency viruses, including HIV and SIV. A method of vaccinating felines with a test vaccine composition is described. Feline animals vaccinated according to the methods and compositions of the invention exhibit protective humoral and cellular immune responses against FIV when challenged with FIV.

Description

[0001] The present invention was completed with government funding under the research project supported by the National Institutes of Health Fund No. NIHAI30904. The government has certain rights in this invention. [0002] Cross reference of related applications [0003] This application claims the rights of the U.S. Provisional Application Serial No. 60 / 470,066 filed on May 12, 2003, which is hereby incorporated by reference in its entirety along with all its drawings, nucleic acid sequences, amino acid sequences and tables. Background technique [0004] Domestic cats are susceptible to infection by several retroviruses, including feline leukemia virus (FeLV), feline sarcoma virus (FeSV), endogenous type C oncogenic RNA virus (RD-114) and feline syncytium-forming virus (FeSFV). Among these viruses, FeLV is the most important pathogen, which causes a variety of symptoms, including lymphoreticular endothelial cells and myeloma, anemia, immune-mediated disorders, and immunity simila...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/23A61P31/14A61K39/21C07K14/155C07K14/16
CPCC12N2740/15034A61K2039/55522A61K2039/525A61K39/21A61K2039/555C12N2740/15022A61K2039/515C12N2740/16022C07K14/005A61K39/12A61K2039/545A61K2039/55527A61K2039/55538A61K2039/55566A61K2039/57A61P31/14A61P31/18A61P37/02C12N2740/16134C12N2740/16234C07K14/155
Inventor J·K·亚马莫托
Owner UNIV OF FLORIDA RES FOUNDATION INC